Contact
    Start Publications Parallel SPR and QCM-D Quantitative Analysis of CD9, CD63, and ...
    ←  Publication Finder
    QSense

    Parallel SPR and QCM-D Quantitative Analysis of CD9, CD63, and CD81 Tetraspanins: A Simple and Sensitive Way to Determine the Concentration of Extracellular Vesicles Isolated from Human Lung Cancer Cells

    Year: 2023

    Authors: Kowalczyk, Agata; Gajda-Walczak, Aleksandra; Ruzycka-Ayoush, Monika; Targonska, Alicja; Mosieniak, Grazyna; Glogowski, Maciej; Szumera-Cieckiewicz, Anna; Prochorec-Sobieszek, Monika; Bamburowicz-Klimkowska, Magdalena; Nowicka, Anna M.; Grudzinski, Ireneusz P.

    Tetraspanins, including CD9, CD63, and CD81, are transmembrane biomarkers that play a crucial role in regulating cancer cell proliferation, invasion, and metastasis, as well as plasma membrane dynamics and protein trafficking. In this study, we developed simple, fast, and sensitive immunosensors to determine the concentration of extracellular vesicles (EVs) isolated from human lung cancer cells using tetraspanins as biomarkers. We employed surface plasmon resonance (SPR) and quartz crystal microbalance with dissipation (QCM-D) as detectors. The monoclonal antibodies targeting CD9, CD63, and CD81 were oriented vertically in the receptor layer using either a protein A sensor chip (SPR) or a cysteamine layer that modified the gold crystal (QCM-D) without the use of amplifiers. The SPR studies demonstrated that the interaction of EVs with antibodies could be described by the two-state reaction model. Furthermore, the EVs’ affinity to monoclonal antibodies against tetraspanins decreased in the following order: CD9, CD63, and CD81, as confirmed by the QCM-D studies. The results indicated that the developed immunosensors were characterized by high stability, a wide analytical range from 6.1 × 104 particles·mL–1 to 6.1 × 107 particles·mL–1, and a low detection limit (0.6–1.8) × 104 particles·mL–1. A very good agreement between the results obtained using the SPR and QCM-D detectors and nanoparticle tracking analysis demonstrated that the developed immunosensors could be successfully applied to clinical samples.
    View publication